Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AMPH

AMPH - Amphastar Pharmaceuticals Inc Stock Price, Fair Value and News

55.09USD+1.68 (+3.15%)Market Closed
Watchlist

Market Summary

USD55.09+1.68
Market Closed
3.15%

AMPH Stock Price

View Fullscreen

AMPH RSI Chart

AMPH Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

19.51

Price/Sales (Trailing)

4.39

EV/EBITDA

14.05

Price/Free Cashflow

18.87

AMPH Price/Sales (Trailing)

AMPH Profitability

Operating Margin

54.24%

EBT Margin

28.48%

Return on Equity

22.73%

Return on Assets

8.76%

Free Cashflow Yield

5.3%

AMPH Fundamentals

AMPH Revenue

Revenue (TTM)

601.3M

Rev. Growth (Yr)

50.3%

Rev. Growth (Qtr)

23.91%

AMPH Earnings

Earnings (TTM)

135.3M

Earnings Growth (Yr)

210.08%

Earnings Growth (Qtr)

88.42%

Breaking Down AMPH Revenue

Last 7 days

-2.8%

Last 30 days

-0.3%

Last 90 days

-3.2%

Trailing 12 Months

70.2%

How does AMPH drawdown profile look like?

AMPH Financial Health

Current Ratio

2.1

Debt/Equity

1.07

Debt/Cashflow

0.27

AMPH Investor Care

Buy Backs (1Y)

0.88%

Diluted EPS (TTM)

2.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023518.6M540.9M601.3M0
2022455.1M476.9M484.9M499.0M
2021368.2M384.0M412.8M437.8M
2020327.3M334.0M337.3M349.8M
2019316.1M324.1M328.7M322.4M
2018241.9M247.8M265.4M294.7M
2017252.5M249.6M243.3M240.2M
2016254.0M268.2M268.5M255.2M
2015221.5M226.3M230.5M251.5M
2014222.6M209.1M209.5M210.5M
2013210.7M217.0M223.3M229.7M
2012000204.3M

Tracking the Latest Insider Buys and Sells of Amphastar Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
petersen floyd f.
sold
-26,548
53.0968
-500
-
Jan 10, 2024
luo mary z.
sold
-7,171,770
54.5855
-131,386
coo,chief scientist & chairman
Jan 09, 2024
luo mary z.
sold
-4,923,230
57.1432
-86,156
coo,chief scientist & chairman
Jan 08, 2024
luo mary z.
sold
-7,875,480
58.9288
-133,644
coo,chief scientist & chairman
Jan 02, 2024
petersen floyd f.
sold
-30,682
61.3659
-500
-
Dec 04, 2023
zhou rong
acquired
56,891
16.19
3,514
senior evp, production center
Dec 04, 2023
zhou rong
sold
-209,364
59.58
-3,514
senior evp, production center
Dec 01, 2023
petersen floyd f.
sold
-28,952
57.9044
-500
-
Dec 01, 2023
zhou rong
acquired
62,150
14.4
4,316
senior evp, production center
Dec 01, 2023
zhou rong
sold
-252,831
58.58
-4,316
senior evp, production center

1–10 of 50

Which funds bought or sold AMPH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 23, 2024
CIM, LLC
new
-
479,908
479,908
0.07%
Feb 21, 2024
Raleigh Capital Management Inc.
added
15.22
3,487
9,834
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
4,283
16,700
-%
Feb 16, 2024
VIMA LLC
new
-
15,932
15,932
0.04%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
3.03
10,102,000
36,304,000
-%
Feb 15, 2024
Financial Gravity Asset Management, Inc.
unchanged
-
-
31.00
-%
Feb 15, 2024
State of Wyoming
reduced
-39.05
-11,126
50,593
0.01%
Feb 15, 2024
Legal & General Group Plc
added
0.13
1,704,640
6,623,270
-%
Feb 15, 2024
MERCER GLOBAL ADVISORS INC /ADV
new
-
210,000
210,000
-%
Feb 15, 2024
BARCLAYS PLC
added
165
2,818,000
3,912,000
-%

1–10 of 46

Are Funds Buying or Selling AMPH?

Are funds buying AMPH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMPH
No. of Funds

Unveiling Amphastar Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
5.88%
2,814,710
SC 13G/A
Feb 09, 2024
zhang jack y.
26.2%
13,435,210
SC 13G/A
Jan 23, 2024
blackrock inc.
12.6%
6,037,158
SC 13G/A
Jan 17, 2024
federated hermes, inc.
6.83%
3,272,761
SC 13G/A
Feb 09, 2023
vanguard group inc
5.42%
2,621,807
SC 13G/A
Feb 01, 2023
federated hermes, inc.
6.80%
3,284,217
SC 13G/A
Jan 27, 2023
zhang jack y.
25.5%
13,110,695
SC 13G/A
Jan 26, 2023
blackrock inc.
14.6%
7,038,769
SC 13G/A
Jan 20, 2023
blackrock inc.
14.6%
7,038,769
SC 13G/A
Feb 14, 2022
federated hermes, inc.
7.24%
3,464,335
SC 13G/A

Recent SEC filings of Amphastar Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 02, 2024
4
Insider Trading
Feb 01, 2024
144
Notice of Insider Sale Intent
Jan 23, 2024
SC 13G/A
Major Ownership Report
Jan 17, 2024
SC 13G/A
Major Ownership Report
Jan 11, 2024
4
Insider Trading
Jan 10, 2024
4
Insider Trading
Jan 10, 2024
144
Notice of Insider Sale Intent
Jan 09, 2024
144
Notice of Insider Sale Intent

What is the Fair Value of AMPH?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Amphastar Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
387.3B
93.0B
-3.60% -2.76%
11.02
4.16
6.46% 95.94%
156.7B
46.5B
-3.76% -37.06%
-112.89
3.37
42.59% -114.62%
153.4B
28.2B
-7.44% 18.02%
22.84
5.44
7.09% 2.52%
91.6B
27.1B
-17.13% -16.65%
16.18
3.38
-0.60% 23.36%
14.9B
15.8B
15.02% 26.90%
-26.65
0.94
6.17% 77.01%
MID-CAP
5.0B
1.7B
14.11% 18.79%
14.1
3.02
49.61% 324.78%
4.4B
4.7B
-2.94% -9.06%
-1.1K
0.94
5.74% 96.18%
3.4B
8.8B
-0.23% 18.85%
-5.66
0.38
7.79% -163.11%
2.6B
601.3M
-0.28% 70.16%
19.51
4.39
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.91
1.86
16.26% -147.49%
24.9M
84.1M
58.23% -28.98%
-1.17
0.22
2882.68% -145.15%
24.3M
70.0M
-0.88% -54.80%
0.36
0.34
-19.54% 888.31%
18.0M
111.1M
-6.33% -18.68%
-1.13
0.16
-10.43% 84.90%
2.0M
20.0M
-35.83% -91.10%
-0.15
0.1
137.71% 66.04%

Amphastar Pharmaceuticals Inc News

Latest updates
AmericanBankingNEWS26 hours ago
Investor's Business Daily3 months ago

Amphastar Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue23.9%18114614013512012312012111210210396.0083.0086.0085.0083.0080.0079.0080.0090.0076.00
Cost Of Revenue-1.1%72.0073.0066.0064.0062.0060.0065.0065.0061.0054.0058.0059.0047.0053.0048.0050.0045.0047.0049.0055.0046.00
Gross Profit49.0%10873.0074.0071.0059.0063.0056.0056.0051.0047.0045.0037.0037.0033.0037.0033.0035.0032.0031.0035.0029.00
Operating Expenses-0.3%36.0036.0040.0033.0035.0039.0034.0032.0026.0037.0035.0034.0033.0036.0029.0034.0033.0031.0034.0033.0027.00
  S&GA Expenses-4.6%6.007.007.005.005.006.006.004.005.004.005.004.004.004.003.003.003.003.003.003.002.00
  R&D Expenses-1.1%17.0017.0020.0017.0019.0023.0016.0017.0011.0018.0015.0018.0018.0016.0015.0020.0019.0016.0015.0017.0011.00
EBITDA Margin20.6%0.36*0.30*0.28*0.28*0.26*0.29*0.29*0.24*0.18*0.11*0.07*0.07*---------
Interest Expenses280.4%14.004.000.001.001.000.000.000.001.000.000.000.000.000.000.000.000.000.000.000.000.00
Income Taxes119.7%14.006.007.007.007.006.004.007.007.006.001.00-0.952.00-0.072.000.001.0014.00-1.48-1.131.00
Earnings Before Taxes94.0%64.0033.0034.0041.0023.0023.0029.0027.0038.0014.005.00-6.747.00-1.506.001.002.0061.00-3.631.003.00
EBT Margin18.3%0.28*0.24*0.23*0.23*0.21*0.25*0.24*0.19*0.12*0.05*0.01*0.01*---------
Net Income88.4%49.0026.0026.0034.0016.0017.0024.0020.0030.008.005.00-6.274.00-0.194.00-1.031.0048.001.002.002.00
Net Income Margin19.4%0.22*0.19*0.18*0.18*0.16*0.19*0.18*0.14*0.09*0.03*0.01*0.00*---------
Free Cashflow18.0%54.0046.0031.009.0015.00-3.1545.0034.00-4.6526.0015.008.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets12.1%1,5451,378774742727724716672652666646631614600573587586601545514481
  Current Assets41.2%543385408378384377364318304311300280277267247255269284230220195
    Cash Equivalents79.5%26714917715615716617312710712510295.0090.0089.0057.0076.0087.0012281.0088.0071.00
  Inventory5.1%11010510410410399.0095.0093.0010098.0097.0097.0010910510811111099.0079.0069.0065.00
  Net PPE0.8%281279243238233238243244243253253260246238231234222220215210203
Liabilities20.3%949789225213222224237226222199195183163158149159152169164149139
  Current Liabilities2.7%25825110695.0010210411410498.0012512711297.0093.0083.0090.0087.0010111210797.00
  Long Term Debt30.7%63848873.0073.0074.0074.0074.0075.0076.0030.0032.0034.0033.0035.0036.0039.0038.0040.0031.0032.0033.00
Shareholder's Equity1.0%595589549529505499480446430467451449451442423428434432380364341
  Retained Earnings15.2%37332429827223822220518016113112311812412012011611711668.0067.0066.00
  Additional Paid-In Capital1.4%478471457455449443433422413427414410404397371367362355349344330
Shares Outstanding-1.9%48.0049.0048.0048.0049.0049.0048.0048.0048.0048.0048.0047.00---------
Minority Interest----------45.0045.0046.0046.0045.0046.0046.0044.0044.0045.0032.0022.00
Float------885---482---567---638---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations17.1%64,33454,92340,38215,22620,3752,81550,76540,4412,56932,15922,82516,8938,80730,0891,4775,652-12,00351,723-3,6109,51715,781
  Share Based Compensation-4.5%4,6444,8656,1114,3044,2994,2355,0223,8503,9196,0844,8344,3334,3706,5135,2824,2954,2944,0324,6743,9103,908
Cashflow From Investing93.9%-31,152-508,582-6,333-229-15,258-8,180-9,110-11,954-3,769-4,254-8,695-12,176-5,451-10,066-8,722-7,352-18,622-9,669-14,884-8,797-12,876
Cashflow From Financing-79.8%86,613428,111-13,548-16,162-13,931-9944,648-8,696-16,492-5,191-6,639-227-3,02612,456-11,449-10,382-3,888-74211,22916,92217,804
  Buy Backs38963.3%50,0011288,01518,06914,4946,1171,22913,4366,0935,5613,7833,3904,3295,75610,95013,7774,4261,0733,0152,6077,590

AMPH Income Statement

2023-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Net Revenues:    
Total net revenues$ 180,556$ 120,129$ 466,290$ 363,964
Cost of revenues72,15361,619211,309186,272
Gross profit108,40358,510254,981177,692
Operating expenses:    
Selling, distribution, and marketing6,4074,78420,23416,059
General and administrative12,65411,98438,41834,433
Research and development16,66418,51453,32257,535
Total operating expenses35,72535,282111,974108,027
Income from operations72,67823,228143,00769,665
Non-operating income (expenses):    
Interest income1,2023313,156741
Interest expense(13,702)(566)(17,702)(1,318)
Other income (expenses), net3,459(397)1,5535,692
Total non-operating income (expenses), net(9,041)(632)(12,993)5,115
Income before income taxes63,63722,596130,01474,780
Income tax provision14,0256,55927,16016,187
Income before equity in losses of unconsolidated affiliate49,61216,037102,85458,593
Equity in losses of unconsolidated affiliates(390)(163)(1,476)(1,120)
Net income (loss)$ 49,222$ 15,874$ 101,378$ 57,473
Net income per share    
Basic (in Dollars per share)$ 1.01$ 0.32$ 2.10$ 1.18
Diluted (in Dollars per share)$ 0.91$ 0.30$ 1.91$ 1.09
Weighted-average shares used to compute net income per shares    
Basic (in Shares)48,70148,90448,36848,635
Diluted (in Shares)53,92152,78852,99752,665
Product revenues, net    
Net Revenues:    
Total net revenues$ 151,855$ 120,129$ 437,589$ 363,964
Other revenues    
Net Revenues:    
Total net revenues$ 28,701 $ 28,701 

AMPH Balance Sheet

2023-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 266,778$ 156,098
Restricted cash4,259235
Short-term investments33,09819,664
Restricted short-term investments2,2002,200
Accounts receivable, net118,99088,804
Inventories109,978103,584
Income tax refunds and deposits1,506171
Prepaid expenses and other assets6,1967,563
Total current assets543,005378,319
Property, plant, and equipment, net280,836238,266
Finance lease right-of-use assets610753
Operating lease right-of-use assets32,66625,554
Investment in unconsolidated affiliate1,0262,414
Goodwill and intangible assets, net619,35137,298
Long-term investments972 
Other assets25,29920,856
Deferred tax assets40,86838,527
Total assets1,544,633741,987
Current liabilities:  
Accounts payable and accrued liabilities222,71984,242
Income taxes payable31,0924,571
Current portion of long-term debt4333,046
Current portion of operating lease liabilities3,7193,003
Total current liabilities257,96394,862
Long-term reserve for income tax liabilities7,2257,225
Long-term debt, net of current portion and unamortized debt issuance costs638,20672,839
Long-term operating lease liabilities, net of current portion30,19923,694
Deferred tax liabilities201144
Other long-term liabilities15,69914,565
Total liabilities949,493213,329
Stockholders' equity:  
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding
Common stock: par value $0.0001; 300,000,000 shares authorized; 59,220,178 and 47,898,466 shares issued and outstanding as of September 30, 2023 and 58,110,231 and 48,112,069 shares issued and outstanding as of December 31, 2022, respectively66
Additional paid-in capital477,880455,077
Retained earnings373,102271,723
Accumulated other comprehensive loss(8,411)(8,624)
Treasury stock(247,437)(189,524)
Total equity595,140528,658
Total liabilities and stockholders' equity$ 1,544,633$ 741,987
AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
 CEO
 WEBSITEwww.amphastar.com
 EMPLOYEES1615

Amphastar Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Amphastar Pharmaceuticals Inc? What does AMPH stand for in stocks?

AMPH is the stock ticker symbol of Amphastar Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amphastar Pharmaceuticals Inc (AMPH)?

As of Mon Feb 26 2024, market cap of Amphastar Pharmaceuticals Inc is 2.64 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMPH stock?

You can check AMPH's fair value in chart for subscribers.

What is the fair value of AMPH stock?

You can check AMPH's fair value in chart for subscribers. The fair value of Amphastar Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amphastar Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amphastar Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AMPH is over valued or under valued. Whether Amphastar Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Amphastar Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMPH.

What is Amphastar Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Feb 26 2024, AMPH's PE ratio (Price to Earnings) is 19.51 and Price to Sales (PS) ratio is 4.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMPH PE ratio will change depending on the future growth rate expectations of investors.